Loading the SOTA2 catalog…
Verge Labs
Uses proprietary human tissue data and AI to develop drugs for neurological diseases, operating under the Verge Labs and Verge Genomics brands.
- Founded
- Not disclosed
- Headquarters
- Not disclosed
- Company size
- 11–50
- Products tracked
- 3
Products by Verge Labs
Pricing for Verge Labs
Contact sales
Contact Verge Labs for current plans, volume pricing, and enterprise terms.
Trust profile
Security and compliance
No compliance claims have been published for this company.
administrative_safeguards
physical_safeguards
technical_safeguards
Latest updates from Verge Labs
Product launchResearch
Verge Labs Launches vBx-1.0 Foundation Model for Precision Neurology
Verge Labs introduced vBx-1.0, a foundation model designed for precision neurology. The model is trained on proprietary brain transcriptome and clinical data to reconstruct the molecular state of a patient's brain from blood samples. It is intended to help predict disease progression and treatment response, aimed at improving clinical trial efficacy. The model is currently available for preview via the company's CONVERGE platform, with ongoing efforts to validate performance on clinical trial datasets from drug development partners.
InvestorEli LillyInvestorBlackRockInvestorY CombinatorPartnerTenacia Biotechnology